sulfinpyrazone has been researched along with Phlegmasia Alba Dolens in 40 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Phlegmasia Alba Dolens: Inflammation that is characterized by swollen, pale, and painful limb. It is usually caused by DEEP VEIN THROMBOSIS in a FEMORAL VEIN, following PARTURITION or an illness. This condition is also called milk leg or white leg.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two highly sensitive models of arterial and venous thrombosis forming with the test of endothelial stability a complementary system with a maximum stress on the role of vascular lesion were used to test a series of four antithrombotic drugs (heparin, acetylsalicylic acid, dipyridamole, sulfinpyrazone) and four drugs with other indications but with an antithrombotic activity in experiment (prenylamine, troxerutin, ketanserin and pizotifen)." | 3.67 | Antithrombotics in view of thrombosis models. ( Hladovec, J, 1986) |
| "A patient with recurrent thrompophlebitis had sterile pyuria with white blood cell casts and transient, mild renal failure during therapy with sulfinpyrazone." | 3.65 | Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy. ( Braun, J, 1976) |
| " It is concluded that when initiating and withdrawing treatment with SP in a patient receiving AC, the prothrombin time should be checked daily for a few days to adapt (reduce) the dosage of AC to the change in prothrombin time induced by SP." | 2.65 | [The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol]. ( Fontanilles, F; Holt, NF; Michot, F, 1981) |
| "Dipyridamole can inhibit both platelet adhesion and aggregation by raising the platelet cyclic AMP level through phosphodiesterase inhibition." | 2.37 | Aspirin and other platelet-aggregation inhibiting drugs. ( Gallus, AS, 1985) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 40 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genton, E | 5 |
| Sautter, RD | 2 |
| Koch, EL | 1 |
| Myers, WO | 1 |
| Ray, JR | 1 |
| Mazza, JJ | 1 |
| Larson, DE | 1 |
| Chen, HM | 1 |
| Milbauer, JP | 1 |
| Treuhaft, PS | 1 |
| Plotka, ED | 1 |
| Ordinas, A | 1 |
| Bouchier-Hayes, D | 1 |
| Nenci, GG | 1 |
| Agnelli, G | 1 |
| Berrettini, M | 1 |
| Niada, R | 1 |
| Mantovani, M | 1 |
| Prino, G | 1 |
| Pescador, R | 1 |
| Porta, R | 1 |
| Berti, F | 1 |
| Folco, GC | 1 |
| Omini, C | 1 |
| Viganò, T | 1 |
| Verstraete, M | 3 |
| Weiss, HJ | 2 |
| Michot, F | 1 |
| Holt, NF | 1 |
| Fontanilles, F | 1 |
| Sloan, RW | 1 |
| Turpie, AG | 2 |
| Warlow, CP | 1 |
| Schöndorf, TH | 1 |
| Croveri, G | 1 |
| Lagarde, M | 1 |
| Dechavanne, M | 1 |
| Steele, P | 1 |
| Ellis, J | 1 |
| Hirsh, J | 4 |
| Rogers, PH | 1 |
| Walsh, PN | 1 |
| Marder, VJ | 1 |
| Bosak, GC | 1 |
| Lachman, JW | 1 |
| Ritchie, WG | 1 |
| Oppenheimer, L | 1 |
| Sherry, S | 1 |
| Yasunaga, K | 1 |
| Oelz, O | 1 |
| Deykin, D | 1 |
| Gallus, AS | 2 |
| Gruber, UF | 1 |
| Buser, P | 1 |
| Frick, J | 1 |
| Loosli, J | 1 |
| Matt, E | 1 |
| Segesser, D | 1 |
| Braun, J | 1 |
| Arfors, KE | 1 |
| Bergqvist, D | 1 |
| Tangen, O | 1 |
| Gent, M | 1 |
| Harker, LA | 2 |
| Hladovec, J | 2 |
| Veth, G | 1 |
| Meuwissen, OJ | 1 |
| van Houwelingen, HC | 1 |
| Sixma, JJ | 1 |
| Didisheim, P | 1 |
| Kazmier, FJ | 1 |
| Fuster, V | 1 |
| Forbes, CD | 1 |
| Prentice, CR | 1 |
| Steele, PP | 1 |
| Weily, HS | 1 |
14 reviews available for sulfinpyrazone and Phlegmasia Alba Dolens
| Article | Year |
|---|---|
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
[Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
Topics: Anticoagulants; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Flurbiprof | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
Antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyridamole; Hea | 1981 |
Cerebrovascular disease.
Topics: Anticoagulants; Antifibrinolytic Agents; Aspirin; Blood Platelets; Cerebrovascular Disorders; Fibrin | 1981 |
[Indications and uncertainties of antiaggregating agents].
Topics: Anticoagulants; Aspirin; Clofibrate; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregati | 1977 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
Antiplatelet drugs in thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Drug Therapy, Combination; | 1979 |
Antithrombotic drugs: part II.
Topics: Anabolic Agents; Ancrod; Animals; Aspirin; Blood Platelets; Clofibrate; Dextrans; Dipyridamole; Fibr | 1976 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
Aspirin and other platelet-aggregation inhibiting drugs.
Topics: Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Female; Heart Valv | 1985 |
Platelet inhibition in the management of thrombosis.
Topics: Aspirin; Blindness; Blood Platelets; Cell Survival; Cerebrovascular Disorders; Dextrans; Dipyridamol | 1974 |
Anticoagulants.
Topics: Anticoagulants; Aspirin; Blood Platelet Disorders; Dipyridamole; Enzyme Therapy; Factor IX; Factor V | 1974 |
12 trials available for sulfinpyrazone and Phlegmasia Alba Dolens
| Article | Year |
|---|---|
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Aspirin-sulfinpyrazone in prophylaxis of deep venous thrombosis in total hip replacement.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Fema | 1983 |
[The effect of sulfinpyrazone on the coagulation-inhibiting action of acenocoumarol].
Topics: Acenocoumarol; Adult; Aged; Arterial Occlusive Diseases; Blood Coagulation; Clinical Trials as Topic | 1981 |
[Thrombosis prevention with thrombocyte aggregation inhibitors in the venous system].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Platelet Aggregation; Sulfinpyrazone; Throm | 1982 |
Internation Committee on Thrombosis and Haemostasis Basil, 8.-11. September 1974 Subcommittee on Clinical Investigations: Registry of prospective clinical trials.
Topics: Ancrod; Animals; Arterial Occlusive Diseases; Aspirin; Batroxobin; Clinical Trials as Topic; Fibrino | 1975 |
Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Blood Platelets; Cell Survival; Clinical Trials as Topic; Ethylestrenol | 1978 |
Drug therapy: antiplatelet therapy (second of two parts).
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical T | 1978 |
Controlled trial of low-dose heparin and sulfinpyrazone to prevent venous thromboembolism after operation on the hip.
Topics: Administration, Oral; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heparin; Hi | 1978 |
[Clinical application and evaluation of anti-platelet agents].
Topics: Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; | 1978 |
The effect of platelet function inhibitors on experimental venous thrombosis formation in rabbits.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Collagen; Dipyri | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts).
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clofibrate; Dipyridamole; Drug Evaluation; Fibrin | 1975 |
Prevention of postoperative deep vein thrombosis by a combination of subcutaneous heparin with subcutaneous dihydroergotamine or oral sulphinpyrazone.
Topics: Adult; Dihydroergotamine; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Pos | 1985 |
15 other studies available for sulfinpyrazone and Phlegmasia Alba Dolens
| Article | Year |
|---|---|
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |
Biphasic sulphinpyrazone-warfarin interaction.
Topics: Adult; Drug Synergism; Female; Humans; Sulfinpyrazone; Thrombophlebitis; Warfarin | 1981 |
PGI2-generation and antithrombotic activity of orally administered defibrotide.
Topics: Animals; Aorta; Arachidonic Acid; Arachidonic Acids; Collagen; Cricetinae; DNA; Epoprostenol; Fibrin | 1982 |
Antiplatelet therapy.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprost | 1981 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
Increase of platelet prostaglandin cyclic endoperoxides in thrombosis.
Topics: Blood Platelets; Clofibrate; Collagen; Dipyridamole; Heparin; Humans; Peroxides; Prospective Studies | 1977 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
Antithrombotic therapy. Rationale and application.
Topics: Anticoagulants; Arteries; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; D | 1979 |
Sulfinpyrazone and postoperative deep vein thrombosis.
Topics: Administration, Oral; Adult; Dextrans; Drug Evaluation; Fibrinogen; Heparin; Humans; Injections, Int | 1977 |
Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy.
Topics: Acute Kidney Injury; Adult; Blood Urea Nitrogen; Creatinine; Humans; Male; Nephritis, Interstitial; | 1976 |
A sensitive model of venous thrombosis in rats.
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Disease Models, Animal; Female; Heparin; Ketanserin; | 1986 |
Antithrombotics in view of thrombosis models.
Topics: Animals; Anticoagulants; Arteries; Aspirin; Dipyridamole; Female; Hydroxyethylrutoside; Ketanserin; | 1986 |
Etiology and prevention of thromboembolic disease. Taming a complex circulatory malfunction.
Topics: Antithrombin III Deficiency; Aspirin; Blood Coagulation Disorders; Catheters, Indwelling; Contracept | 1986 |
Recognizing and reacting to recurrent pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Blood Platelet Disorders; Fibrinolytic Agents; Heparin; Humans | 1973 |
Platelet survival and adhesiveness in recurrent venous thrombosis.
Topics: Adult; Anticoagulants; Blood Platelets; Cell Survival; Chromium Isotopes; Female; Humans; Male; Midd | 1973 |